UPDATE 3-Immunomedics soars as lupus drug shows promise

Positive Phase IIb results for UCB, Immunomedics drug

LONDON/BRUSSELS, Aug 27 (Reuters) - Immunomedics (IMMU.O) became the second biotech company in just over a month to report success in the fight against lupus on Thursday, sending its shares more than 50 percent higher.